New insights into diagnosis and therapeutic options for proliferative hepatoblastoma

Autor: Christophe Grosset, Benoit Rousseau, Thérèse Commes, Katarzyna B. Hooks, Tony Ernault, Nathalie Dugot-Senant, Anne Rullier, Anne-Aurélie Raymond, Marie-Annick Buendia, Jérôme Audoux, Sophie Branchereau, Laurence Brugières, Monique Fabre, Coralie Danet, Sarah Lesjean, Martin Hagedorn, Helena Fazli, Thierry Leste-Lasserre, Sophie Taque, Catherine Guettier

Publikováno v: Hepatology
Hepatology, Wiley-Blackwell, 2018, 68 (1), pp.89-102. ⟨10.1002/hep.29672⟩
Hepatology, 2017, 1, ⟨10.1002/hep.29672⟩
Hepatology, Wiley-Blackwell, 2017, ⟨10.1002/hep.29672⟩

Surgery and cisplatin-based treatment of hepatoblastoma (HB) currently guarantee the survival of 70%-80% of patients. However, some important challenges remain in diagnosing high-risk tumors and identifying relevant targetable pathways offering new t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adce269c00a9f130c69f151b9a57139e
https://www.hal.inserm.fr/inserm-02437928